Clinical Trial Update: An Open Label Study of the Effects of SHR1459 in NMOSDs Patients [Phase 2]

View source ↗

Summary

Open-label Phase 2 trial assessing the effects of SHR1459 in patients with Neuromyelitis Optica Spectrum Disorders has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuromyelitis Optica Spectrum Disorders

Drugs mentioned

• SHR1459

Snippet

Sponsor: Reistone Biopharma Company Limited | Conditions: Neuromyelitis Optica Spectrum Disorders | Phase 2 | Status: COMPLETED